NCT02877173 - A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

December 31, 2017

Conditions

Arteriosclerosis Obliterans

Interventions

DRUG

Alprostadil Liposomes for Injection

3 doses of Alprostadil Liposomes for Injection are 20ug/q.d,40ug/q.d,60ug/q.d.All groups will be continuous administration for 3 weeks.

DRUG

Alprostadil Injection

Alprostadil Injection(the positive control group):10ug/q.d,continuous administration for 3 weeks.

Trial Locations (1)

RECRUITING

Xuanwu Hospital Capital Medical University, Beijing